Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

Coming up: earnings from AMD, Palantir, top pharmaceutical and tech firms; private-sector employment report; consumer sentiment.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

PGIM Jennison Growth Fund reviews Q3 underperformance, trims laggards, and adds AI-linked names. See how it targets long-term ...

US stocks finished the first trading day of November mixed, with Big Tech names like Amazon (AMZN) and Nvidia (NVDA) rising ...

Expanded DRAM and HBM output is expected to relieve infrastructure bottlenecks for hyperscalers and data centers amid rising ...